Navigation Links
Novel Treatment Beneficial for Colon and Liver Cancer

A brain child of Leire Garca Navarro, a researcher at the School of Pharmacy at the University of Navarra, has raised hopes for patients suffering colon and liver cancer. The new treatment has shown promise in retarding the growth of such cancers.

This discovery is the principal result of her doctoral dissertation, entitled Lipo-Polymeric Vectors for the Transfer of DNA in Cancer Cells of the Colon, which was subsidized by the Basque Government. In order to carry out the study, this scientist of the Department of Pharmacy and Pharmaceutical Technology used genetic therapy with non-viral vectors for transferring genetic material to the cancerous cells. With this technique, we can assure the therapeutic function of the drug in a wide variety of tissues. In addition, we can apply the treatment repeatedly, since it does not generate immunity, as occurs with viral vectors.

With the objective of improving the effectiveness of this methodology, the specialist worked on designing non-viral systems which act directly upon the liver and the colon. In this manner, she prepared, optimized and evaluated, in vitro and in vivo, a new pharmaceutical format called lipopolyplex. This compound aids the genetic material in penetrating into the damaged cells, and allows drug release in tumorous organs.

Experimentation with the new drug in mice has shown that it slows tumor growth with respect to those animals subjected to other procedures. This diminishing of the cancerogenous area is possible, according to the scientist, thanks to the stimulation of the immune system, since the introduction of the correct gene in the diseased body can cause it to repair itself and destroy the tumor.

In addition, the researcher of the University of Navarra noted that colon cancer alone causes more than 500,000 deaths per year in the West, and currently the only effective treatment is surgery. Despite this treatment, noted the researcher, betwee n 40 and 60% of colon cancer patients die, and for this reason it is important that we seek out treatment based on genetic therapy.-Elhuyar Fundazioa.




'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... ... NuevaCare, a leading home care agency based in San Mateo, California, but ... to announce information upgrades to its blog in the form of WordPress tags. The ... as home care (generally) as well as senior care and home care agency issues. ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation last ... in Neurology Award (PLINA). The couple joins a prestigious list of past PLINA ... Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. , ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: